Ascentage Pharma Group International income statement

In fiscal 2025, Ascentage Pharma Group International reported revenue of $79.9m, down 41.4% on the year before and net income of −$173m, or −$1.94 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ascentage Pharma Group International: income statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	31	31	136	80
Cost of revenue	3	4	4	7
Gross profit	28	27	132	73
Research and development	111	100	132	158
General and administrative	25	26	26	34
Interest expense	1	0	0	0
Income before tax	−132	−132	−55	−172
Income tax	−1	−1	1	1
Net income	−131	−131	−56	−173
Diluted EPS	−$2.00	−$1.85	−$0.74	−$1.94
Diluted shares (average)	66m	71m	76m	89m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AAPG vs ADCT AAPG vs PLX AAPG vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ascentage Pharma Group International's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ascentage Pharma Group International.